Filing Flows › Xeris Biopharma Holdings (XERS) › Operating margin
Xeris Biopharma Holdings (XERS) operating margin by quarter
Xeris Biopharma Holdings' operating margin was 15.8% in Q3 2026 (third quarter 2026), +6.3 pts from Q1 2026. Over the last 4 quarters it ranged from 9.0% (Q3 2025) to 19.5% (Q4 2025).
| Quarter | Operating margin | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | 15.8% | +6.3 pts | +6.7 pts |
| Q1 2026 | 9.5% | -10.0 pts | — |
| Q4 2025 | 19.5% | +10.5 pts | — |
| Q3 2025 | 9.0% | — | — |
Q3 2026 at a glance
Xeris Biopharma Holdings, Q3 2026: revenue $107M (+44% year over year), operating margin 15.8%, net earnings $11.3M, operating cash flow $35.5M. The chart follows the revenue to costs, profit and cash.
Questions
What is Xeris Biopharma Holdings' operating margin?
Xeris Biopharma Holdings' operating margin was 15.8% in Q3 2026 (third quarter 2026), +6.3 pts from Q1 2026.
How has Xeris Biopharma Holdings' operating margin changed?
Over the last 4 quarters it ranged from 9.0% (Q3 2025) to 19.5% (Q4 2025).
Q3 2026 results → · How Xeris Biopharma Holdings makes money →